3 Body USA offers a generative AI platform that transforms intellectual property-based videos into various artistic styles, utilizing exclusive datasets from the Three-Body Problem trilogy for machine learning training. This technology enables content creators to enhance their visual storytelling by providing diverse stylistic options, thereby increasing audience engagement and creative expression.

Aerovate Therapeutics is developing AV-101, a proprietary dry powder inhaled formulation of imatinib, to target the hyperproliferation of cells in the narrowed arteries of patients with pulmonary arterial hypertension (PAH). This approach aims to provide significant health improvements for individuals suffering from this rare and progressive cardiopulmonary disease.

Agita Labs develops privacy-enhanced computing architectures that utilize cryptographic techniques to facilitate secure data sharing and monetization. This technology enables organizations to exchange sensitive data while maintaining strict privacy and security standards.

Algoritmica develops machine learning systems for private credit investment, focusing on data enrichment, predictive modeling, and AI governance. The company addresses the need for enhanced decision-making in finance by providing tailored analytics that leverage unique asset-backed securities data.

Alphina Therapeutics develops antibody-drug conjugates (ADCs) that utilize novel NAMPT inhibitor payloads to target and eliminate both dividing and non-dividing tumor cells. The company pairs these next-generation ADC candidates with a proprietary diagnostic test to precisely identify patients most likely to respond to NAMPT inhibitor therapy. This precision approach aims to deliver superior, effective cancer treatments for a broader patient population than existing targeted therapies.

This company develops small molecule antiviral drugs targeting infections caused by HPV, herpes viruses, HIV, and animal retroviruses. Their medicinal chemistry platform aims to create direct-acting antivirals, helping patients recover from viral diseases.

Aria Pharmaceuticals utilizes artificial intelligence to accelerate drug discovery and development processes in the biopharmaceutical sector. The company focuses on identifying novel therapeutic targets and optimizing candidate selection, reducing time and costs associated with bringing new drugs to market.

Arrakis Therapeutics is developing RNA-targeted small molecule therapeutics to address neurological disorders and other diseases by utilizing a novel RNA degradation approach. Their focus on rSM medicines aims to improve treatment efficacy and patient outcomes in complex disease areas.

ArsenalBio develops programmable CAR T-cell therapies specifically targeting solid tumors, utilizing a computationally driven approach to enhance treatment efficacy. The company addresses the challenge of treating cancer's complex nature by engineering cell therapies that aim to improve patient outcomes.

Artizan Biosciences specializes in drug discovery and development targeting diseases linked to the human intestinal microbiota through advanced microbiome analysis and therapeutic interventions. The company aims to improve patient outcomes by developing precise treatments that restore microbial balance and enhance gut health.

AssetWatch provides a deployable, remote condition monitoring solution that utilizes vibration, temperature, and oil analysis to detect machine issues before they lead to failure. By enabling proactive maintenance, the platform helps organizations reduce unplanned downtime and save significantly on repair costs.

Atsena Therapeutics is a clinical-stage gene therapy company utilizing adeno-associated virus (AAV) technology to develop treatments for inherited retinal diseases, specifically targeting X-linked retinoschisis and GUCY2D-associated Leber congenital amaurosis. Their ongoing Phase I/II clinical trials aim to reverse or prevent vision loss in patients suffering from these genetic conditions.

The startup develops boron neutron capture therapy (BNCT) technology that precisely targets and delivers boron to cancer cells, effectively eliminating solid tumors while preserving healthy tissue. This approach enhances treatment efficacy for various cancers, improving patient outcomes through targeted therapy.

Beam Therapeutics develops precision genetic medicines using base editing technology to enable targeted modifications of DNA sequences. This approach addresses the limitations of traditional gene editing methods, offering potential treatments for genetic disorders with improved accuracy and reduced off-target effects.

BioAge provides a cloud‑based platform that generates multi‑omics biomarkers to quantify an individual’s biological age and predict health‑span trajectories. The service integrates genomics, transcriptomics, proteomics and metabolomics data with machine‑learning models, delivering calibrated age scores via a HIPAA‑compliant API and web dashboard for use by clinicians and pharmaceutical trial teams to personalize interventions and stratify study cohorts.

Brimstone develops a decarbonized process for producing ordinary portland cement that meets ASTM C150 standards, significantly reducing CO2 emissions associated with cement production. Their technology aims to eliminate 120,000 metric tons of CO2 annually, addressing the cement industry's contribution to 7.5% of global CO2 emissions.

Cardior Pharmaceuticals develops non-coding RNA-based therapeutics, specifically CDR132L, to reverse adverse cardiac remodeling in heart failure patients following myocardial infarction. Their approach targets the underlying mechanisms of heart disease, aiming to restore normal cellular functions and improve patient outcomes.

Cartesia provides a real-time text-to-speech (TTS) API featuring expressive capabilities like AI laughter and emotion for conversational agents. This streaming TTS service offers ultra-low latency and context-aware accuracy across over 40 languages. Developers utilize the API for building engaging, human-like voice interactions in applications like customer support and gaming.

The startup develops next-generation cell therapies utilizing stem cell biology, immunology, and gene editing to treat cancer and autoimmune diseases. By focusing on T cells and other immune cells, the company provides stem cell-derived medicines that enhance treatment efficacy for patients facing these serious health challenges.

HARM provides an AI-powered platform for individuals experiencing harm to quickly access immediate, trusted support. The system intelligently identifies the nature of the reported harm and routes users directly to appropriate, city-approved advocacy, legal, or housing resources. This streamlined process eliminates confusion while generating de-identified data insights to help municipal leaders optimize community support services.

Labs develops human-enhancement technologies that utilize artificial intelligence, immersive realities, and consumer-wearables to foster community engagement and improve individual capabilities. The company addresses the need for interconnected social experiences and sustainable practices by providing tools that empower users to learn, create, and collaborate effectively.

Ro operates a telehealth platform that provides online clinics for weight loss, sexual health, hair restoration, and fertility management using clinically proven treatments and prescription medications. The service eliminates the need for insurance and offers free, discreet shipping, making healthcare accessible and convenient for over 2 million members.

Science is a clinical-stage technology company developing biohybrid neural interfaces and advanced neural recording electronics to address serious unmet medical needs in neuroscience. Their technologies aim to enhance neural communication and restore vision, facilitating new treatment possibilities for patients with neurological disorders.

The startup operates an online retail marketplace that connects customers with surplus and deadstock building materials and DIY products from retailers. By offering these goods at significantly reduced prices, the platform addresses the issue of waste in the construction industry while providing affordable options for consumers.